190 likes | 357 Views
Erlotinib in advanced NSCLC. In phase III study (BR.21), erlotinib produced significant survival, symptom and quality-of-life benefits in patients with advanced NSCLC who had failed prior chemotherapy1better outcomes seen in some patient subgroupsRetrospective analyses have generated predictive bi
E N D
1. MERIT: A prospective study of putative relationships between tumour biomarkers and clinical benefit from erlotinib in advanced non-small-cell lung cancer (NSCLC) Tan E-H, Ramlau R, Pluzanska A, Kuo H-P Klughammer B, Kockx M, Carreras MLutz V, Essioux L, Baselga J
2. Erlotinib in advanced NSCLC In phase III study (BR.21), erlotinib produced significant survival, symptom and quality-of-life benefits in patients with advanced NSCLC who had failed prior chemotherapy1 better outcomes seen in some patient subgroups Retrospective analyses have generated predictive biomarker hypotheses epidermal growth factor receptor (EGFR) expression EGFR gene copy number mutations in tyrosine-kinase (TK) domain of EGFR Further investigation of markers, and validation of current hypotheses is warranted